For the fiscal year ending March 2026, consolidated revenue was JPY 2,139.2 billion (up 11.9% YoY), operating income was JPY 382.6 billion (up 832.4% YoY), and net income attributable to owners of parent was JPY 291.5 billion (up 474.5% YoY). An annual dividend of JPY 78 per share is planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-04-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4503-20260427-02.pdf","jir_short_summary":"For the fiscal year ending March 2026, consolidated revenue was JPY 2,139.2 billion (up 11.9% YoY), operating income was JPY 382.6 billion (up 832.4% YoY), and net income attributable to owners of parent was JPY 291.5 billion (up 474.5% YoY). An annual dividend of JPY 78 per share is planned.","jir_summary":"### Performance Overview\nConsolidated revenue for the fiscal year ending March 2026 reached JPY 2,139.2 billion (up 11.9% YoY), driven by expanded sales of key strategic products PADCEV, IZERVAY, VYLOY, VEOZAH, and XTANDI. Operating income rose significantly to JPY 382.6 billion (up 832.4% YoY), while net income attributable to owners of parent also increased sharply to JPY 291.5 billion (up 474.5% YoY). On a core basis, operating income was JPY 555.7 billion (up 41.6% YoY) and core net income was JPY 424.4 billion (up 43.5% YoY), demonstrating improved profitability. Research and development expenses were controlled at JPY 314.8 billion (down 3.9% YoY).\n\n### Financial Position and Dividends\nAt the end of the fiscal year ending March 2026, total assets amounted to JPY 3,567.0 billion (an increase of JPY 227.5 billion from the previous term), total equity reached JPY 1,830.9 billion (up JPY 317.6 billion), and the equity ratio attributable to owners of parent rose to 51.3%. The annual dividend was set at JPY 78 (including a year-end dividend of JPY 39), marking an increase of JPY 4 from the previous term. Earnings guidance for the fiscal year ending March 2027 anticipates consolidated revenue of JPY 2,220.0 billion (up 3.8% YoY), core operating income of JPY 620.0 billion (up 11.6% YoY), core net income of JPY 460.0 billion (up 8.4% YoY), and an annual dividend of JPY 80 (interim JPY 40, year-end JPY 40).","jir_financial_highlights":"Revenue: 2,139,245 million JPY (Up 11.9% YoY)\nOperating Income: 382,633 million JPY (Up 832.4% YoY)\nNet Income Attributable to Owners of Parent: 291,535 million JPY (Up 474.5% YoY)\nAnnual Dividend (per share): 78 JPY (Up 4 JPY YoY)\nOutstanding Shares (Common Stock): 1,809,663,075 shares (No change from previous term)","jir_category":"","jir_hashtags":"#AstellasPharma, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 2,139.2 billion (up 11.9% YoY)\nOperating Income: JPY 382.6 billion (up 832.4% YoY)\nNet Income Attributable to Owners of Parent: JPY 291.5 billion (up 474.5% YoY)","jir_meta_title":"[Astellas Pharma] FY March 2026 Financial Results\uff5cRevenue JPY 2,139.2 billion (YoY +11.9%)","jir_meta_description":"Astellas Pharma's financial summary for fiscal year ending March 2026. Revenue of JPY 2,139.2 billion (up 11.9% YoY), operating income of JPY 382.6 billion (up 832.4% YoY), and annual dividend of JPY 78 announced. Earnings growth anticipated in FY March 2027.","jir_og_title":"[Astellas Pharma] FY March 2026 Financial Results\uff5cRevenue JPY 2,139.2 billion (YoY +11.9%)","jir_og_description":"Astellas Pharma financial summary for fiscal year ending March 2026. Significant increases in revenue, operating income, and net income. Dividend increase planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025\\\",\\\"FY March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1912323,2139245],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025\\\",\\\"FY March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[41039,382633],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025\\\",\\\"FY March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[50747,291535],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"dividend_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Annual Dividend Trend (JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025\\\",\\\"FY March 2026\\\",\\\"FY March 2027 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Annual Dividend\\\",\\\"data\\\":[74,78,80],\\\"backgroundColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Income and Core Net Income Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025\\\",\\\"FY March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income\\\",\\\"data\\\":[392435,555681],\\\"borderColor\\\":\\\"#59a14f\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Core Net Income\\\",\\\"data\\\":[295682,424413],\\\"borderColor\\\":\\\"#edc948\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"major_products_sales\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Growth in Sales of Major Products (100 million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"PADCEV\\\",\\\"IZERVAY\\\",\\\"VYLOY\\\",\\\"VEOZAH\\\",\\\"XOSPATA\\\",\\\"XTANDI\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY March 2025\\\",\\\"data\\\":[1641,583,122,338,680,9123],\\\"backgroundColor\\\":\\\"#9c755f\\\"},{\\\"label\\\":\\\"FY March 2026\\\",\\\"data\\\":[2212,776,631,466,718,9608],\\\"backgroundColor\\\":\\\"#bab0ac\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"regional_sales\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Regional Revenue Trends (100 million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"United States\\\",\\\"Japan\\\",\\\"Established Markets\\\",\\\"China\\\",\\\"International Markets\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY March 2025\\\",\\\"data\\\":[8664,2670,4854,783,2035],\\\"backgroundColor\\\":\\\"#ff9da7\\\"},{\\\"label\\\":\\\"FY March 2026\\\",\\\"data\\\":[9402,2890,5636,1015,2307],\\\"backgroundColor\\\":\\\"#9c755f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-42897","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n